Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Addy C, Tatosian D, Glasgow XS, Gendrano IN 3rd, Kauh E, Martucci A, Johnson-Levonas AO, Selverian D, Matthews CZ, Gutierrez M, Wagner JA, Aubrey Stoch S. Addy C, et al. Among authors: tatosian d. Clin Ther. 2016 Mar;38(3):516-30. doi: 10.1016/j.clinthera.2015.12.020. Epub 2016 Feb 9. Clin Ther. 2016. PMID: 26869191 Clinical Trial.
A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.
Tatosian DA, Cardillo Marricco N, Glasgow XS, DeGroot B, Dunnington K, George L, Gendrano IN, Johnson-Levonas AO, Swearingen D, Kauh E. Tatosian DA, et al. Clin Pharmacol Drug Dev. 2016 Sep;5(5):383-92. doi: 10.1002/cpdd.260. Epub 2016 Apr 29. Clin Pharmacol Drug Dev. 2016. PMID: 27627194 Clinical Trial.
Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
Jain L, Chain ASY, Tatosian DA, Hing J, Passarell JA, Kauh EA, Lai E. Jain L, et al. Among authors: tatosian da. Br J Clin Pharmacol. 2019 Dec;85(12):2759-2771. doi: 10.1111/bcp.14103. Epub 2019 Dec 9. Br J Clin Pharmacol. 2019. PMID: 31454094 Free PMC article.
Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects.
Krishna R, Addy C, Tatosian D, Glasgow XS, Gendrano Iii IN, Robberechts M, Haazen W, de Hoon JN, Depré M, Martucci A, Peng JZ, Johnson-Levonas AO, Wagner JA, Stoch SA. Krishna R, et al. Among authors: tatosian d. J Clin Pharmacol. 2016 Dec;56(12):1528-1537. doi: 10.1002/jcph.773. Epub 2016 Jun 17. J Clin Pharmacol. 2016. PMID: 27225334 Free PMC article. Clinical Trial.
Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection.
Krug AW, Vaddady P, Railkar RA, Musser BJ, Cote J, Ederveen A, Krefetz DG, DeNoia E, Free AL, Morrow L, Chakravarthy MV, Kauh E, Tatosian DA, Kothare PA. Krug AW, et al. Among authors: tatosian da. Clin Transl Sci. 2017 Sep;10(5):404-411. doi: 10.1111/cts.12479. Epub 2017 Jul 20. Clin Transl Sci. 2017. PMID: 28727908 Free PMC article. Clinical Trial.
Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging.
Van Laere K, De Hoon J, Bormans G, Koole M, Derdelinckx I, De Lepeleire I, Declercq R, Sanabria Bohorquez SM, Hamill T, Mozley PD, Tatosian D, Xie W, Liu Y, Liu F, Zappacosta P, Mahon C, Butterfield KL, Rosen LB, Murphy MG, Hargreaves RJ, Wagner JA, Shadle CR. Van Laere K, et al. Among authors: tatosian d. Clin Pharmacol Ther. 2012 Aug;92(2):243-50. doi: 10.1038/clpt.2012.62. Epub 2012 Jun 27. Clin Pharmacol Ther. 2012. PMID: 22739139
27 results